semaglutide for office use of new diet drugs likely to mushroom— Harvard Gazette McKee's proposed FY2027 budget drops

A 2024 retrospective cohort analysis published in Diabetes, Obesity and Metabolism (N=312 patients who switched from semaglutide to tirzepatide at a single academic center) found that switchers lost an additional mean of 6.3% of body weight over 6 months after the switch, with 68% reporting either stable or improved GI tolerability [12]

An additive residual error model on log-transformed concentration values was assessed to adequately describe the data

Thats HALF PRICE

Food aversions represent the most frequently reported taste-related change

Compounded semaglutide also acts as a GLP-1 receptor agonist and is customized for each patient

Its more medically complex than general weight counseling and requires coordination with prescribing providers